

# Financial Tear Sheet

## Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

## Stock Information

### FCSC (Common Stock)

<b>Exchange</b>	NASDAQ CM (US Dollar)
<b>Financial Status Indicator</b>	D
<b>Price</b>	<b>\$0.67</b>
<b>Change (%)</b>	0.00 (1.52%)
<b>Volume</b>	118,843
<b>52 Week Low</b>	\$0.61
<b>Market Cap</b>	\$17,275,300
<b>Rolling EPS</b>	-1.81
<b>PE Ratio</b>	N/A
<b>Shares Outstanding</b>	25,900,000

Data as of 02/16/18 3:59 p.m. ET



## Recent Headlines & Events

02/06/18 - 8:01 a.m.  
Fibrocell to Present at 20th Annual BIO CEO & Investor Conference

Date	Title
04/17/18	<b>Alliance for Regenerative Medicine — 6th Annual Cell &amp; Gene Therapy Investor Day</b>

02/05/18 - 8:01 a.m.

Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma

01/30/18 - 8:01 a.m.

Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

**Location** New York, NY

04/25/18 2:00 p.m. ET

**8th Annual World Orphan Drug Congress USA 2018**

**Location** Oxon Hill, MD – Washington, DC metro area

## SEC Filings

Filing Date	Form
02/13/18	SC 13G/A
02/12/18	8-K
02/05/18	8-K
01/30/18	8-K

## Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

## Ownership Summary

### Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	41	8.15	56.0	12,560,250
Mutual Fund	13	.24	1.5	333,909
Director and Officer	1	.25	0.5	105,600

\*Insider values reflect direct beneficial ownership.

### Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	8,267,413	36.9	2,727,273	12/31/17
Sabby Management, LLC	1,128,588	5.0	1,128,588	12/31/17
MSD Partners, L.P.	692,960	3.1	0	12/31/17
Armistice Capital LLC	613,896	2.7	613,896	12/31/17
Anson Funds Management LP.	448,136	2.0	448,136	12/31/17
The Vanguard Group, Inc.	267,280	1.2	-61,296	12/31/17
FNY Partners Fund LP	200,000	0.9	200,000	12/31/17
Point72 Asset Management, L.P.	200,000	0.9	200,000	12/31/17
Renaissance Technologies LLC	128,796	0.6	10,032	12/31/17
Creative Planning, Inc.	93,090	0.4	32,000	12/31/17

Data provided by Nasdaq. Minimum 15 minutes delayed.